Murky FDA Device Guidance Kills Sanofi Antitrust Suit
Sanofi reasonably filed a patent for its insulin injector in the FDA's Orange Book, since the agency wasn't clear about whether it should, and rationally defended that patent against possible infringement,...To view the full article, register now.
Already a subscriber? Click here to view full article